关于Biomobie

百慕迪是一家拥有多项生物电“无创血管正常化”全球专利的再生医学机构,其 IT研发中心和产品设计中心位于美国硅谷,医疗临床研发基地位于美国波士顿,产品应用及生产基地位于中国上海。


Biomobie率先成功研发出了全球第一组无创血管再生专利技术“百慕迪生物电”技术,该技术的诞生突破了血管微循环受损难于修复的医学难题。“循环障碍会引发人体的414种疾病和33种恶性肿瘤,他是万病之源。人体微循环好了,95%的病可以不治而愈。”百慕迪经过上万例的临床验证证实,修复人体血管微循环可以达到同时康复多种慢性疾病的目的。


“百慕迪生物电”技术面市2年以来,经历了上万例患者的无创血管再生疗程后,统计数据显示有十几种慢性疾病甚至包括一些无药可救的血管慢病也同样可以通过血管再生达到“不治而愈”的目的。这一颠覆性的人体血管再生技术对于延长人类寿命,减少住院概率以及未来的医保方案将产生深远的影响; 为慢性疾病的预防和治疗增添了一种极为安全、有效的解决方案。


“百慕迪生物电”技术对血管病变的无创修复应用已在高血压防治领域获得上海食品药品监督管理局(SFDA)的二类医疗器械市场准入。在临床后研究中发现,该技术对心脏病、脑卒中、糖尿病足、静脉曲张、男性功能障碍以及失眠等症状有独特的表现,进一步的临床试验已在美国哈佛大学附属布莱根医院及美国梅奥医院展开。该技术有望成为医药、疫苗之后第三种针对血管疾病防治的有效新疗法。


Biomobie is a regenerative medical organization with a number of bio-power "noninvasive vascular normalization" global patents. Its IT research and development centers and product design centers are located in Silicon Valley, USA. The medical research and development base is located in Boston, USA. The product application and production base is located in China Shanghai.


Biomobie took the lead in successfully developed the world's first group of non-invasive vascular regeneration patented technology "Bermudi bio-electric" technology, the birth of the technology broke through the vascular microcirculation damage difficult to repair the medical problems. "Circulatory disorders will cause the body's 414 kinds of diseases and 33 kinds of malignant tumors, he is the source of all diseases. Human microcirculation is good, 95% of the disease can be dead and more." Bermudian after thousands of cases of clinical validation confirmed, Repair human vascular microcirculation can achieve the purpose of recovering a variety of chronic diseases at the same time.


"Biomobie bio-electricity" technology 2 years since the experience of thousands of patients with noninvasive vascular regeneration course, the statistics show that a dozen chronic diseases and even some of the disease can not save the slow disease can also be passed Vascular regeneration to achieve the "incurable and more" purpose. This disruptive human vascular regeneration technique will have a profound impact on prolonging human life, reducing the probability of hospitalization, and future health care programs; adding an extremely safe and effective solution to the prevention and treatment of chronic diseases.


"Biomobie Biotechnology" technology for non-invasive repair of vascular disease applications in the field of hypertension prevention and control of the Shanghai Food and Drug Administration (SFDA) of the second class of medical equipment market access. In the post-clinical study found that the technology for heart disease, stroke, diabetic foot, varicose veins, male dysfunction and insomnia and other symptoms have a unique performance, further clinical trials have been in the United States Harvard University affiliated Braggen Hospital and the United States Mayo Hospital. The technology is expected to become a new vaccine for the prevention and treatment of vascular disease after the new treatment.

公司展望

Company outlook

百慕迪拥有的生物再生因子库和生物电子医药库由几十种电子配方组成,其中促成内皮祖细胞再生的百慕迪R7 BBT-I只是其中的一种。世界卫生组织预测,下个世纪将是预防医学为主的医疗体系。百慕迪R7的两大因子库将成为在西医和中医之后一个全新的生命预防康复医疗体系。这一体系代表着先进的预防医学。其通过帮助体内器官组织细胞恢复生长,调节体内细胞的活性和代谢水平,从而促进各种慢性病自身康复,堪称是未来朝阳医学。百慕迪R7的研发成功,是人体再生医学领域的一大颠覆性突破,必将成为人类生命医学史上一个重要的里程碑。


Biomobie Bio-Regeneration Factor Library and Bioelectronics Library are made up of dozens of electronic recipes, and the Bermudy R7 BBT-I, which contributes to the regeneration of endothelial progenitor cells, is just one of them. The World Health Organization predicts that the next century will be a preventive medicine-based health care system. Bermudy R7's two major factor libraries will become a new life prevention medical system after Western medicine and Chinese medicine. This system represents advanced preventive medicine. It is through the help of organ tissue cells to restore growth, regulate the activity of cells and metabolic levels, thereby promoting a variety of chronic diseases themselves, called the future of Chaoyang Medical. Bermudy R7 R & D success, is the field of human regenerative medicine a subversive breakthrough, will become an important milestone in the history of human life medicine.

 

Biomobie 全部产品细节都已经过国家专利版权保护
未经授权不得以任何方式盗用或模仿
违者必究

Biomobie all product details have been over the nationanl patent copyright protection Without authorization
shall not be used in any way to steal or imitate
Those who violate the law will be subject to legal sa

Biomobie (shanghai) Regenerative Medicine co., Ltd.

扫描二维码分享到微信